Back to School: How biopharma can reboot drug development. Access exclusive analysis here

China increasing scrutiny for IPOs

The China Securities Regulatory Commission (CSRC) is increasing scrutiny of IPO applications through internal measures and regulatory mechanisms. The commission published a draft document proposing a stringent set

Read the full 287 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE